🔗 Share this article

The first new treatments for gonorrhoea in decades are being viewed as a "huge turning point" in the battle against drug-resistant strains of the infection, according to scientists.

A Global Public Health Issue

Cases of gonorrhoea are on the rise around the world, with estimates suggesting in excess of 82 million infections annually. Particularly high rates are reported in Africa and nations within the World Health Organization's Western Pacific region, which spans from China and Mongolia to New Zealand. In England, cases have reached a all-time high, while figures across Europe in 2023 were three times higher compared to the rates from 2014.

“The approval of novel therapies for gonorrhoea is an important and timely development in the context of increasing worldwide cases, the spread of superbugs and the highly restricted available drugs at this time.”

Public health authorities are deeply concerned about the rise in antibiotic-resistant strains. The global health body has designated it as a "high-priority threat". Recent surveillance found that resistance to key first-line drugs like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

A Pair of Novel Drugs Gain Approval

Zoliflodacin, also known as a brand name, was cleared by the US Food and Drug Administration in December for combating gonorrhoea. This disease can lead to major issues, including infertility. Researchers anticipate that focused deployment of this new drug will help hinder the development of resistance.

Another new antibiotic, created by the pharmaceutical company GSK, gained clearance in close succession. This medication, which is additionally indicated for UTIs, was demonstrated in studies to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

A Novel Approach to Creation

Zoliflodacin emerged from a innovative non-profit model for medication research. The charitable organization GARDP worked alongside the drug firm Innoviva to develop it.

“This authorization signifies a significant shift in the treatment of highly resistant gonorrhoea, which until now has been staying ahead of our drug pipeline.”

Research Study Data and Worldwide Availability

Based on findings published in a prominent scientific publication, the new drug cured over nine in ten of genital gonorrhoea infections. This establishes an equal footing with the existing first-line therapy, which uses an injection and a pill. The study enrolled over 900 participants from several countries including the United States, Thailand, South Africa, and European nations.

Under the terms of its development partnership, the non-profit has the ability to make available and distribute the drug in many regions with limited resources.

Clinicians on the front lines have expressed optimism. Having a single-dose, oral treatment of this kind is described as a "revolutionary step" for managing the epidemic. This is deemed crucial to reduce the burden of the illness for patients and to halt the transmission of highly drug-resistant gonorrhoea around the world.